Advertisement
Product › Details
CB307 (Crescendo Biologics)
Next higher product group | therapeutic antibody | |
Status | 2021-05-10 development p2 existent | |
Organisation | Crescendo Biologics Ltd. | |
Crescendo Biologics Ltd.. (5/10/21). "Press Release: Crescendo Biologics further Strengthens Leadership Team with Appointment of Dr Michael Booth as Chief Financial Officer". Cambridge.
Crescendo Biologics Ltd (Crescendo), a clinical-stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces the appointment of Dr Michael Booth as Chief Financial Officer (CFO). Mike joins with over 20 years’ experience in corporate finance within the biopharmaceutical industry.
Mike joins Crescendo at an important stage of its development, following the initiation of its Phase Ia/Ib trial for Crescendo’s lead Humabody® programme, CB307, a first-in-class PSMAxCD137 T cell enhancer. Mike will be responsible for Crescendo’s financial strategy and reporting, as well as global investor relations.
Prior to joining Crescendo, Mike served as Division Vice President, Investor Relations & Corporate Responsibility at Incyte (NASDAQ:INCY). Beforet hat, he was Senior Vice President, Communications & Corporate Affairs at Algeta ASA, where he was responsible for corporate communications and capital markets strategies. Prior to Algeta, Mike was Managing Director at The Trout Group, where he helped build the European client base of biotech and healthcare companies, delivering strategic and investor relations consultancy services. He has also held pan-European biotechnology equity research roles at Canaccord, Bank of America, and UBS Investment Bank. Mike earned his DPhil in Neuroscience from the University of Oxford and graduated from the University of St Andrews with a BSc in Psychology.
“We are delighted to welcome Mike to the team. His proven track record and wide-ranging financial expertise and relationships will be crucial as Crescendo enters its next phase of growth.” commented Theodora Harold, CEO of Crescendo. “We now have a highly experienced team in place, committed to progressing our pipeline of innovative, first-in-class, T cell enhancing programmes. I am confident Mike will add tremendous value as Crescendo looks to achieve its full potential.”
Dr Michael Booth, CFO of Crescendo, said: “Crescendo is an ambitious company with a unique platform and an innovative pipeline of T cell enhancing therapeutics. This is a very exciting time to join the team, given that the first clinical trial for CB307, the lead Humabody® programme, is now underway.”
A high-resolution headshot of Dr Michael Booth is available upon request.
-Ends-
For more information, please contact:
Crescendo Biologics
Theodora Harold, CEO
+44 (0) 1223 497140
investors@crescendobiologics.com
media@crescendobiologics.com
Instinctif Partners
Melanie Toyne-Sewell, Siobhan Sanford, Nathan Billis
+44 (0) 20 7457 2020
crescendo@instinctif.com
AboutCrescendoBiologics
Crescendo Biologics is a private, clinical-stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137xPSMA Humabody® for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anticancer effect whilst avoiding systemic toxicity.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody®VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.
Beyond Crescendo’s proprietary pipeline, the Company has a global, multi-target discovery and development collaboration with Takeda, a clinical development partnership with Cancer Research UK and an exclusive, worldwide licensing agreement with Zai Lab.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.
For more information, please visit www.crescendobiologics.com and follow @HUMABODY.
Record changed: 2023-07-26 |
Advertisement
More documents for therapeutic antibody
- [1] Adrenomed AG. (4/10/24). "Press Release: AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock". Hennigsdorf....
- [2] InflaRx N.V.. (2/22/24). "Press Release: InflaRx Appoints Jan Medina as Head of Investor Relations". Jena....
- [3] InflaRx N.V.. (1/25/24). "Press Release: InflaRx Announces Initiation of Its Commitment Program for GOHIBIC (vilobelimab) to Help Broaden Access for Eligible Patients". Ann Arbor, MI....
- [4] WuXi Biologics. (1/11/24). "Press Release: WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates". Shanghai....
- [5] Calypso Biotech B.V.. (1/8/24). "Press Release: Calypso Enters into Agreement to Be Acquired by Novartis". Amsterdam....
- [6] SanReno Therapeutics. (1/5/24). "Press Release: SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease". Shanghai....
- [7] EMBL. (12/14/23). "Press Release: Using Artificial Intelligence to Discover Therapeutic Antibodies"....
- [8] Heidelberg Pharma AG. (11/29/23). "Press Release: Heidelberg Pharma Announces Changes to the Executive Management Board. CEO Dr. Jan Schmidt-Brand to Retire". Ladenburg....
- [9] Boehringer Ingelheim. (11/28/23). "Press Release: Boehringer Ingelheim and IBM Collaborate to Advance Generative AI and Foundation Models for Therapeutic Antibody Development". Ingelheim & Armonk, NY....
- [10] Roche. (10/23/23). "Press Release: Roche Enters into a Definitive Agreement to Acquire Telavant". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top